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Abstract
Background: The nuclear receptor farnesoid-X-receptor (FXR; NR1H4) is expressed not only in the liver, gut, kidney
and adipose tissue but also in the immune cells. FXR has been shown to confer protection in several animal models of
inflammation, including experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
FXR agonists are currently tested in clinical trials for treatment of human metabolic diseases. The beneficial effect of
FXR agonists in EAE suggests that FXR might represent a potential target in inflammatory-demyelinating CNS diseases,
such as MS. In MS, oligodendrocytes not only undergo cell death but also contribute to remyelination. This repair
mechanism is impaired due to a differentiation block of oligodendroglial progenitor cells. Activation of other nuclear
receptors that heterodimerize with FXR promote oligodendroglial differentiation. Therefore, we wanted to address the
functional relevance of FXR for glial cells, especially for oligodendroglial differentiation.
Methods: We isolated primary murine oligodendrocytes from FXR-deficient (FXR Ko) and wild-type (WT) mice
and determined the effect of FXR deficiency and activation on oligodendroglial differentiation by analysing
markers of oligodendroglial progenitor cells (OPCs) and mature oligodendrocytes (OLs) using qRT-PCR and
immunocytochemistry. Additionally, we determined whether FXR activation modulates the pro-inflammatory
profile of astrocytes or microglia and whether this may subsequently modulate oligodendroglial differentiation. These
in vitro studies were complemented by histological analyses of oligodendrocytes in FXR Ko mice.
Results: FXR is expressed by OPCs and mature oligodendrocytes. However, lack of FXR did not affect oligodendroglial
differentiation in vitro or in vivo. Furthermore, activation of FXR using the synthetic agonist GW4064 did not affect
oligodendroglial differentiation, remyelination in an ex vivo model or the expression of pro-inflammatory molecules in
astrocytes or microglia. Concordantly, no effects of supernatants from macrophages cultured in the presence of GW4064
were observed regarding a possible indirect impact on oligodendroglial differentiation.
Conclusions: Our data suggest that FXR is dispensable for oligodendroglial differentiation and that FXR agonists, such as
GW4064, represent a potential therapeutic approach for MS which specifically targets peripheral immune cells including
macrophages but not brain-resident cells, such as oligodendrocytes, astrocytes or microglia.
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Background
Nuclear receptors are a large group of transcription fac-
tors that comprises 49 family members which enable the
organism to quickly adapt to environmental changes by
inducing the appropriate gene program [1]. Nuclear re-
ceptors are activated by lipophilic ligands including hor-
mones, fatty acids, bile acids and oxysterols, homo- and
heterodimerize upon activation and regulate the metab-
olism of glucose, fatty acids, triglycerides and lipopro-
teins [1]. Besides these metabolic effects, numerous
immune-modulatory effects by nuclear receptors have
been described, including modulation of central nervous
system (CNS) autoimmunity [2–4].
Interestingly, several members of the nuclear receptor
family are also involved in molecular mechanisms regu-
lating oligodendroglial differentiation. Downregulation
of retinoid X receptor gamma (RXRγ) expression or ap-
plication of RXRγ antagonists significantly impaired
oligodendroglial differentiation. Similarly, mice lacking
RXRγ showed delayed remyelination after induction of
demyelination in vivo [5]. In oligodendrocytes, RXRγ
heterodimerizes with the vitamin D receptor (VDR) to
induce oligodendroglial differentiation, and accordingly,
vitamin D-induced activation accelerates oligodendroglial
differentiation [6]. Other nuclear receptors, such as thy-
roid receptors (TR) and liver X receptors (LXR), are well
expressed in oligodendroglial lineage cells and modulate
oligodendroglial differentiation and myelination. Patients
with congenital hypoparathyroidism typically develop a
hypomyelinating phenotype, and triiodothyronine (T3) is
required for the maturation of oligodendroglial progenitor
cells into mature myelinating oligodendrocytes (for review
see [7]). Mice lacking both LXRα and LXRβ display thin-
ner myelin sheaths and reduced expression levels of mye-
lin genes in the cerebellum. Furthermore, addition of
pharmacological activators of LXRs to mixed glial cell cul-
tures promotes oligodendroglial differentiation [8].
The nuclear receptor farnesoid-X-receptor (FXR;
NR1H4) is expressed not only in the liver, gut, kidney
and adipose tissue, but also in the immune cells [9, 10].
FXR heterodimerizes with other nuclear receptors, such
as RXRs [11, 12]. The best-characterized endogenous
FXR ligands are lipophilic bile acids, namely cholic acid
and chenodeoxycholic acid. In addition, the synthetic
compound GW4064 serves as an agonist with high re-
ceptor specificity and efficacy [11, 13, 14]. In accordance
with its expression pattern, FXR activation has been
shown to confer protection in several animal models of
innate intestinal and hepatic inflammation [11]. In ex-
perimental autoimmune encephalomyelitis (EAE), an
animal model of multiple sclerosis (MS), pharmaco-
logical activation of FXR significantly ameliorated the
disease course by induction of anti-inflammatory macro-
phages [15, 25]. Interestingly, FXR agonists are currently
tested in clinical trials for treatment of alcoholic hepa-
titis, type 2 diabetes mellitus and primary biliary cirrho-
sis, demonstrating that FXR already represents an
attractive pharmacological target in human metabolic
diseases. The beneficial effect of FXR agonists in EAE
suggests that FXR might represent a potential target in
inflammatory-demyelinating CNS diseases, such as MS.
Oligodendroglial lineage cells are not only a primary tar-
get in MS but also a prerequisite for remyelination, an
endogenous repair mechanism. However, especially in
chronic MS lesions, remyelination is limited at least
partly due to a differentiation block inhibiting the differ-
entiation of oligodendroglial progenitor cells (OPCs)
into myelinating oligodendrocytes [16–18]. Importantly,
remyelination failure contributes to axonal damage and
worsening of clinical signs in demyelinating animal
models [19, 20].
Given its recently illustrated relevance in macrophage-
mediated protection from CNS autoimmunity and the
functional role of several nuclear receptors for oligo-
dendroglial differentiation, we addressed the functional
relevance of FXR in different brain-resident cells, espe-
cially focusing on oligodendrocytes. Here, we show that
FXR is expressed in murine oligodendrocytes. However,
lack or activation of FXR did not influence oligodendro-
glial differentiation in vitro or in vivo. Furthermore, FXR
activation did not affect key immune functions of astro-
cytes and microglial cells. These data demonstrate that, in
contrast to other nuclear receptors, FXR is dispensable for
oligodendroglial differentiation as well as for brain-
resident astrocytes and microglia and hence suggest that
pharmacological activation of FXR to downregulate CNS




FXR Ko mice [21] were purchased from Jackson Labora-
tory and C57Bl/6 wild-type control mice from the animal
facility in Münster, Germany. Animal handling and experi-
ments were conducted according to the German Animal
Welfare Act and approved by the responsible governmen-
tal authorities (LANUV Nordrhein-Westfalen; AZ-8.84.-
02.05.20.12.286, 84.-02.04.2013.A029, AZ 84-02.04.2014.
A221, AZ 84-02.04.2013.A374).
Primary oligodendroglial culture and treatment
Primary OPCs were isolated using the immunopanning
method as described earlier [22, 23]. OPCs/differentiat-
ing oligodendrocytes were incubated with 1 or 10 μM
GW4064 (Tocris, 2473) for 24/48 h. Cell viability upon
treatment was measured according to manufacturer’s
protocol using CellTiter-Glo® Luminescent Cell Viability
Assay (Promega, G7570). When treated with bone
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marrow-derived macrophage (BMM) supernatant, oligo-
dendrocytes were incubated with 50% supernatant in
culture medium for 48 h.
Cerebellar slice cultures and treatment
Sagittal, cerebellar slices from P1 mice were dissected as
described earlier [23]. After 12 days in culture, demyelin-
ation was induced by 16-h incubation with 0.5 mg/ml ly-
solecithin. During subsequent remyelination, the brain
slices were incubated with 10 or 20 μM GW4064 for
14 days. The ex vivo slices were fixed and stained with
anti-neurofilament 70 kDa (NFL; Dako, 1:500) and anti-
MBP (Abcam, ab7349, 1:200). Confocal z-stacks of whole
slices were acquired with a Zeiss LSM 700 confocal micro-
scope, and images were analysed using NIH ImageJ. The
extent of myelination was quantified by determining the
ratio between MBP and NFL staining. Two independent
experiments were performed, and in each experiment, six
brain slices and three z-stacks from six brain slices were
analysed for each concentration of GW4064 or DMSO.
Macrophage and microglia culture and treatment
Preparation of bone marrow-derived macrophages and
generation of primary astrocyte cultures via mixed glial
culture preparation were performed as described previ-
ously [2]. The murine embryonic stem cell-derived micro-
glial precursor cells (ESdMs) were provided by Harald
Neumann (University of Bonn) and cultured according to
their publication [2, 24]. Depending on the individual cell
type, cells were treated with different concentrations of
the synthetic FXR agonist GW4064 (Tocris, 2473); con-
centrations depended on individual cell type. Control
groups were treated with the equivalent volume of solvent,
i.e. DMSO. ESdMs and primary astrocytes were incubated
for 24 h with the BMM-conditioned supernatant, before
stimulation with LPS and IFNγ.
Generation of BMM supernatant
To produce BMM-conditioned supernatant, BMMs were
treated with 15 μM GW4064 or DMSO and cultured for
72 h [25].
Detection of TNFα and nitric oxide
TNFα in cell culture supernatants was quantified using
ELISA Ready-SET-Go!® (murine TNFα; eBioscience) ac-
cording to the manufacturer’s recommendations. Nitrite
concentrations were measured in the supernatants using
the Griess Reagent Kit (Invitrogen) according to the
manufacturer’s instructions.
RT2 Profiler™ PCR Array
Treated ESdMs and astrocytes were stimulated with LPS
and INFγ for 6 h. RNA isolation was performed with
RNeasy Mini Kit (Qiagen) combined with the RNase-
Free DNase Set (Qiagen) to digest DNA. For transcrip-
tion to complementary DNA (cDNA), the RT2 First-
Strand Kit (Qiagen) was utilized. Afterwards, the RT2
Profiler™ PCR Array Inflammatory Response & Auto-
immunity (#PAMM-077Z; Qiagen) was performed with
RT2 Real-Time SYBR Green PCR Master Mix (SuperArray
Bioscience) according to the manufacturer’s protocol. For
normalization, the housekeeping gene Hsp90ab1 was
taken as internal control. Analysis was performed at the
RT2 Profiler PCR Array Data Analysis Web portal (pro-
vided from Qiagen).
RNA isolation and qRT-PCR
Total RNA from cells was isolated using peqGOLD Total
RNA Kit (12-6634, PeqLab Biotechnologie GmbH). Mes-
senger RNA (mRNA) was transcribed into cDNA by
reverse transcription reaction (High Capacity cDNATran-
scription Kit, Applied Biosystems), and cDNA was diluted
to a final concentration of 0.75 ng/μl. qRT-PCR was
performed using Power SYBR® Green PCR Master Mix
(Applied Biosystems) and StepOne Plus real-time cycler
(Applied Biosystems). The following primers were used:
Fxr fw: GCCACAGATTTCCTCCTCGT, Fxr rev: CAGT
CTCTCCCTGGTACCCA, Mbp fw: GTACAAGGACTC
ACACACGAGA, Mbp rev: GTTCGAGGTGTCACAA
TGTTCT, RPLP0 fw: CGACCTGGAAGTCCAACTAC
and RPLP0 rev: ATCTGCTGCATCTGCTTG, and data
were normalized using RPLP0 as internal control.
Immunocytochemistry (ICC)
OPCs were fixed directly after seeding or differentiated
and fixed after 48 h as mature oligodendrocytes. Cells
were permeabilised for 10 min in 0.5% Triton X-100 in
PBS and blocked using 5% FCS/PBS for 30 min. The pri-
mary antibodies were rat anti-MBP (Abcam, ab7349,
1:200), rabbit anti-PDGFRα (Santa Cruz, SSC338, 1:300),
rabbit-FXR NR1H4 (Abcam, ab28676, 1:200; or Santa
Cruz sc-13063, 1:100) and mouse anti-Olig2 (Medac,
387M-16, 1:200). Incubation was performed at 4 °C over
night. Secondary antibody staining was performed using
Cy™3 Anti-Rat (1:500) (Jackson, 112-165-167) and anti-
Rabbit Alexa Fluor® 488 conjugate (1:500) (Jackson, 111-
545-144) for 2 h at RT before embedding with Roti®-
Mount FluorCare DAPI (Carl Roth, HP20.1). Images
were taken using the laser scanning microscope (LSM
700, Zeiss Jena). At least 200 cells were quantified, and
the numbers of MBP+ and PDGFRα+ cells were assessed
as percentage of total DAPI+ cells.
Immunohistochemistry (IHC)
Ten-day and 8-week-old WT or FXR Ko mice were
sacrificed and intracardially perfused. The spleens, spinal
cords and brains were removed and fixed in 4% PFA
overnight. Paraffin sections (4 μm) were pretreated with
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citrate buffer (pH 6) and stained using an automated
immunostainer (AutostainerLink 48, Dako). Primary
antibodies were specific to FXR (NR1H4, rabbit, Abcam
ab28676 1:200; or Santa Cruz sc-13063, 1:50), NogoA
(mouse, 11c7, a generous gift from M.E. Schwab, Brain
Research Institute, University of Zürich and Department
of Biology, Swiss Federal Institute of Technology Zürich,
Switzerland, 1:15,000) and Olig2 (rabbit, 18953, IBL,
1:150 and mouse, 387M-16, Medac, 1:200). Numbers of
oligodendroglial cells were quantified in a blinded fash-
ion in the corpus callosum, cerebellum and spinal cord
in standardized microscopic fields of 10,000 μm2 each
defined by an ocular morphometric grid.
Statistics
All cell culture experiments were performed in tripli-
cates and replicated at least three times. All statistical
analyses were performed using GraphPad Prism 5.03
(GraphPad Software Inc., San Diego, CA). In text and
figures, results are provided as mean ± SEM. Multiple
comparisons in the same data set were analysed by the
Bonferroni-corrected (for selected groups) one-way
ANOVA tests. Single comparisons to control were made
using two-tailed Student’s t test. p values <0.05 were
considered significant.
Results
FXR is expressed in oligodendrocytes
Histological analysis of brain sections from adult mice
revealed expression of FXR in oligodendroglial lineage
cells, which were identified by their typical linear ar-
rangement within the corpus callosum (Fig. 1a (arrows))
and by coexpression with OLIG2 (Fig. 1b). Additionally,
we analysed expression of FXR in oligodendrocytes in
vitro. Before induction of differentiation using CNTF
and NT3 [22], almost 100% of the oligodendroglial
lineage cells express PDGFRα, a marker specifically
expressed by OPCs. After 24 h of differentiation, ap-
proximately 15% of the cells express MBP, a marker of
mature oligodendrocytes; this percentage increases to
35% after 48 h, whereas PDGFRα+ OPCs account for
approximately 10% of the cells. FXR protein expression
was detected in OPCs and mature oligodendrocytes
using immunocytochemistry (Fig. 1c). Quantification of
Fxr gene expression demonstrated an increase in Fxr
Fig. 1 FXR is expressed by oligodendroglial cells in vivo and in vitro. Immunohistochemical analysis revealed oligodendroglial cells in the corpus
callosum of adult mice express FXR protein. Oligodendrocytes were identified by their linear arrangement (arrows) and coexpression of OLIG2,
respectively (a, b). In primary, murine oligodendroglial cells, FXR is expressed in OLIG2+ OPCs and mature oligodendrocytes, identified by OLIG2
and MBP expression after 48 h of in vitro differentiation (c). The relative Fxr gene expression level is increased in mature oligodendrocytes compared to
OPC (d), n = 3; two-tailed Student’s t test, *p < 0.05; all images are representative
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mRNA expression during oligodendroglial differentiation
(Fig. 1d).
Lack of FXR does not impair oligodendroglial
differentiation in vivo or in vitro
Utilizing FXR Ko mice, we determined the impact of
FXR loss on the numbers of oligodendrocytes 10 days
and 8 weeks after birth. To determine the numbers of
OPCs and mature oligodendrocytes, we used OLIG2, a
transcription factor that is expressed in both cell popula-
tions. Quantification of OLIG2+ cells in the corpus cal-
losum, cerebellum and spinal cord of FXR Ko and WT
mice did not reveal differences between the two geno-
types (Fig. 2a, c). Additionally, the number of mature
NogoA positive oligodendrocytes was not affected by
loss of FXR in any of the analysed CNS regions (Fig. 2b, d).
The differentiation of FXR Ko or WT oligodendrocytes
isolated from either cerebrum or cerebellum was ex-
amined in vitro (Fig. 2e–h). After 24 h of differenti-
ation, Mbp expression levels were slightly reduced in
FXR Ko cells; however, no significant alteration in
gene expression could be observed in either cerebral
or cerebellar oligodendrocytes (Fig. 2e, g). In addition,
no difference in the amount of PDGFRα+ OPCs or
MBP+ mature oligodendrocytes could be detected
comparing FXR Ko and WT cells (Fig. 2f, h). In sum-
mary, lack of FXR had no major effect on the numbers of
oligodendrocytes or oligodendroglial differentiation, nei-
ther in vivo nor in vitro.
Activation of FXR does not affect oligodendroglial
differentiation
OPCs isolated either from the cerebrum or from the cere-
bellum were treated with 1 or 10 μM of the pharmaco-
logical FXR agonist GW4064 after induction of
differentiation for up to 48 h. GW4064 treatment did not
affect the viability of the oligodendroglial cells (data not
shown). mRNA expression levels of the myelin-associated
gene Mbp increased over time, but no differences in the
relative expression levels were detected between GW4064-
treated and control-treated oligodendrocytes (Fig. 3a).
Using immunocytochemistry, we determined the num-
ber of PDGFRα+ OPCs and MBP+ mature oligodendro-
cytes after 48 h of GW4064 treatment. The addition of
Fig. 2 Loss of FXR does not impact oligodendroglial differentiation in vitro and in vivo. Immunohistochemical staining of WT and FXR Ko mice,
either 10 days or 8 weeks old, display no differences in the number of OLIG2+ oligodendroglial cells in the corpus callosum (cc), cerebellum or
spinal cord (a, c). In addition, the proportion of mature NOGO A+ oligodendrocytes (b, d) is not altered in FXR Ko mice compared to WT mice. In
vitro cultured, primary oligodendrocytes isolated either from the cerebrum (e, f) or cerebellum (g, h) display no significant difference in the Mbp
gene expression (e, g) after 24 and 48 h of differentiation or the percentage of PDGFRα+ OPCs or mature MBP+ oligodendrocytes (f, h) after 48 h
of differentiation. In vivo: number of cells/mm2 was determined using an ocular grit, n = 4–6 animals, two-tailed Student’s t test; in vitro: n = 3,
one-way ANOVA with Bonferroni’s correction, 200 cells per condition and two-tailed Student’s t test, ns >0.05; all images are representative
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GW4064 to oligodendroglial cell cultures did not result
in a significant change in the percentage of PDGFRα+
OPCs or MBP+ mature oligodendrocytes (Fig. 3b, c).
Additionally, we analysed the impact of GW4064 appli-
cation to oligodendroglial cells isolated from the cere-
bellum; however, no alterations in Mbp gene expression
or changes in the percentage of PDGFRα+ OPCs and
MBP+ mature oligodendrocytes compared to controls
were observed (Additional file 1: Figure S1a–c). These
data show that direct activation of FXR has no impact
on oligodendroglial differentiation.
Remyelination following toxic-induced demyelination in
cerebellar brain cultures is not impacted by activation of
FXR
To analyse a potential impact of FXR activation on the
process of remyelination, we made use of cerebellar slice
cultures that were demyelinated by lysolecithin. We ap-
plied two different concentrations of GW4064 to demye-
linated cerebellar slice cultures during 14 days of
remyelination. Evaluation of the amount of MBP+ and
NFL+ axons revealed no influence of GW4064 treatment
on the remyeliation capacity of oligodendrocytes after
toxic demyelination in this ex vivo model (Additional file 1:
Figure S1g, h).
No indirect effect of FXR-activated macrophages on
oligodendroglial differentiation
Since peripheral macrophages migrate into the CNS dur-
ing MS pathogenesis and then modulate the inflamma-
tory activity of brain-resident cells and given the strong
immune-modulatory properties of FXR in macrophages
[25], we next addressed whether FXR might indirectly
affect oligodendrocytes via FXR-modulated macro-
phages. To this end, bone marrow-derived macrophages
(BMM) were cultured and treated with 10 μM GW4064
to activate FXR [25]. Subsequently, OPCs isolated from
the cerebrum were cultured in the presence of superna-
tants from GW4064-exposed BMMs to analyse the effect
on oligodendroglial differentiation. Controls included
oligodendroglial lineage cells cultured either in the
presence of supernatants from BMM without GW4064
exposure or without any BMM supernatants. After 48 h
of differentiation, Mbp expression levels and numbers of
mature MBP+ oligodendrocytes were significantly
reduced in cerebral oligodendrocytes exposed to BMM
supernatants; however, this was independent of GW4064
treatment (Fig. 3d–f ). No significant differences in the
numbers of PDGFRα+ OPCs were observed in cul-
tures exposed to BMM-conditioned medium with or
without GW4064 or controls (Fig. 3e, f ). Cerebellar
Fig. 3 Cerebral oligodendroglial differentiation is not affected by direct FXR activation or supernatant of FXR-activated BMMs. Cerebral oligodendrocytes
show no differences in Mbp expression when incubated for 24 or 48 h with 1 μM or 10 μM GW4064 compared to control cells treated with solvent (a).
Numbers of PDGFRα+ OPCs and MBP+ oligodendrocytes are not altered due to GW4064 treatment after 48 h (b, c ). Supernatants of BMMs reduce Mbp
gene expression (d) and the percentage of MBP+ oligodendrocytes after 48 h of differentiation, but this effect is independent of GW4064 (e, f ). Percent-
ages of PDGFRα+ OPC are not affected (e, f). n= 3, one-way ANOVA with Bonferroni’s correction, 200 cells per condition, ns >0.05; *p< 0.05; all images
are representative
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oligodendrocytes showed no significant alteration of
Mbp gene expression, but a significant decrease in
MBP+ mature oligodendrocytes after addition of
BMM supernatants compared to controls without BMM
supernatants; however, conditioning with GW4064 had no
additional effect on oligodendroglial differentiation
(Additional file 1: Figure S1d–f ). Furthermore, no sig-
nificant differences in the numbers of PDGFRα+ OPCs
were observed (Additional file 1: Figure S1e, f ).
FXR activation does not affect immune functions of brain-
resident astrocytes and microglia
In light of the described anti-inflammatory properties of
FXR on macrophages [25], we wondered whether
pharmacological FXR activation might suppress inflam-
matory activity of brain-resident astrocytes or microglia,
which could also indirectly influence oligodendrocyte
differentiation and function in local inflammatory pro-
cesses during CNS autoimmunity. However, FXR activa-
tion in primary astrocytes by different concentrations of
GW4064 did not affect the production of key pro-
inflammatory molecules TNFα (Fig. 4a) and NO (Fig. 4b).
In this line, also activation of FXR in embryonic stem
cell-derived microglial cells (ESdMs; [24]) did not sup-
press TNFα (Fig. 4g) and NO (Fig. 4h) production. Fur-
thermore, no differences in the expression of 84 genes
involved in inflammatory immune responses, such as
genes of cytokines, interleukins and chemokines, were
observed in DMSO-treated cells compared to GW4064-
treated astrocytes (Fig. 4c, d) and ESdMs (Fig. 4i, j),
respectively.
Supernatant of GW4064-treated BMMs does not affect
astrocytic and microglial immune functions
We next investigated the influence of conditioned super-
natant from FXR-activated BMMs on astrocytes and
microglial cells. However, there was no modulation of
TNFα (Fig. 4e, k) or NO (Fig. 4f, l) production detectable
in astrocytes as well as in microglial cells upon incubation
with conditioned supernatants. In conclusion, these data
indicate that FXR does not play a major role in controlling
pro-inflammatory activities of brain-resident cells, neither
directly nor indirectly by modulating inflammatory macro-
phage activity.
Discussion
Here, we demonstrate that FXR is expressed by OPCs and
mature oligodendrocytes, like microglia and astrocytes
[25]. However, lack of FXR did not affect oligodendroglial
differentiation in vitro or in vivo. Furthermore, activation
of FXR using the synthetic agonist GW4064 did not affect
oligodendroglial differentiation, ex vivo remyelination or
pro-inflammatory activation of astrocytes or microglia.
Several nuclear receptors, such as RXRα, RXRβ, RXRγ,
VDR, TR, LXRα and LXRβ, are expressed by oligoden-
drocytes and have been shown to affect oligodendroglial
function [5, 6, 8, 26]. Lack of TR or LXRα/LXRβ results
in delayed oligodendroglial differentiation or hypomyeli-
nation in the cerebellum, respectively [8, 26]. Similarly,
blocking and/or downregulation of VDR, TRs or RXRγ
impaired oligodendroglial differentiation [5, 27]. In
contrast, our results provide no indication that lack of FXR
delays oligodendroglial differentiation in vitro or in vivo.
FXR forms a heterodimer with RXR to induce expression
of target genes, but FXR can also function as a repressor
by suppressing gene expression [13]. Our results suggest
that, at least in oligodendrocytes, the function of FXR is re-
dundant to or is compensated by other nuclear receptors.
Activation of several nuclear receptors such as RXRγ,
TR, VDR and LXRα/LXRβ promotes oligodendroglial
differentiation [3, 5–8]. This is in contrast to our results,
which show that activation of FXR by the synthetic
agonist GW4064 had no effect on the number of MBP+
mature oligodendrocytes or expression levels of MBP.
Oligodendrocytes display a region-dependent heterogen-
eity within the CNS [28], and interestingly, lack of
LXRα/β is associated with hypomyelination in the cere-
bellum [8]. To determine whether FXR might play a
more prominent role in the differentiation of cerebellar
oligodendrocytes, we repeated our in vitro experiments
using oligodendrocytes isolated specifically from the
cerebellum. However, neither lack nor activation of FXR
modulated the differentiation of cerebellar oligodendro-
cytes. Likewise, addition of FXR agonists to demyeli-
nated cerebellar slice cultures did not exhibit an effect
on remyelination in this ex vivo model in which exclu-
sively CNS-resident cells are present.
It has recently been shown that activation of FXR in
BMM induced an anti-inflammatory phenotype charac-
terized by downregulation of pro-inflammatory and in-
duction of anti-inflammatory genes [25]. In light of the
finding by Miron and colleagues who demonstrated an
increased differentiation of rodent oligodendrocytes
cultured in the presence of supernatants derived from
anti-inflammatory microglial cells, we hypothesized that
FXR-activated BMM might indirectly modulate oligo-
dendrocyte differentiation [29]. However, our results
provide no evidence that activation of FXR in macro-
phages has a similar, indirect effect on oligodendroglial
differentiation. Oligodendroglial differentiation and
remyelination can also be accelerated in vivo by im-
proved clearance of myelin debris by macrophages as it
has been shown for the RXR agonist bexarotene [30].
Whether activation of FXR in macrophages may poten-
tially result in increased myelin phagocytosis is currently
unknown. However, this could indirectly contribute to
oligodendrocyte differentiation and remyelination.
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The anti-inflammatory phenotype induced by GW4064-
mediated activation of FXR in peripheral myeloid cells,
such as BMMs, is well documented [15, 25]. However, ex-
pression of FXR is not limited to myeloid cells, but is also
present in microglia as well as astrocytes [25]. Interest-
ingly, FXR activation in microglia using GW4064 did not
result in downregulation of pro-inflammatory key mole-
cules, such as TNFα and NO, or altered expression of
pro- and anti-inflammatory genes encoding for cytokines,
interleukins or chemokines as well as their receptors.
These data illustrate that activation of FXR via GW4064
has no influence on the immune responses of microglia
and astrocytes. This contrasts with the activation of other
nuclear receptors such as LXR, RXR and PPARα [31, 32].
Considering previously published data [25], our results
suggest that FXR plays a pivotal role in downregulation of
pro-inflammatory molecules in peripheral myeloid cells,
but not in CNS-resident microglia suggesting heterogen-
eity between the two cell populations despite overlapping
functions. This may be due to a considerable diversity of
gene expression patterns between tissue macrophages
from different mouse organs [33] and could further ex-
plain the recent observation that blood-derived monocytes
might mainly initiate demyelination in EAE whereas
microglia potentially primarily clear myelin debris [34].
Conclusion
In summary, we demonstrated that activation of FXR by
GW4064 does not modulate oligodendroglial differenti-
ation directly or indirectly via FXR activation in macro-
phages. Furthermore, there is no indication that
GW4064 directly or indirectly influences the pro-
Fig. 4 Immune functions of brain-resident astrocytes and microglia are not affected by direct FXR activation or supernatant of FXR-activated
BMMs. The direct treatment with GW4064 (a, b, d, g, h, j) and the incubation with conditioned BMM supernatant of astrocytes (e, f) and ESdMs
(k, l) do not suppress secretion of TNFα and NO. ESdMs and primary astrocytes were treated with different concentrations of GW4064 for 7 days.
RNA was isolated after 6 h of stimulation with LPS and IFNγ. Differential expression of genes was assessed by performing RT2 Profiler PCR Assay
(c, d, i, j). After stimulation, a strong differential expression of genes in astrocytes (c) and ESdM (i) compared to unstimulated cells was detectable.
However, treatment with GW4064 had no influence on the gene expression of either astrocytes (d) or ESdMs (j). Supernatants of pretreated BMMs
were collected after 3 days of culturing and were transferred to ESdMs or astrocytes. Secreted amount of TNFα was determined by ELISA after
stimulation with LPS and IFNγ for 24 h (g, k: ESdMs) or 72 h (a, e: astrocytes). Concentration of produced NO was detected by Griess assay after
48 h of stimulation of ESdMs (h, l) and after 72 h in the supernatant of astrocytes (b, f). Bar graphs: data are represented as mean ± SEM. Shown
is one representative experiment of at least three independent experiments with triplets for each condition, two-tailed Student’s t test. Scatter
plots: data are represented as logarithmic average fold change. Shown are data from two biological replicates
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inflammatory profiles of CNS-resident astrocytes or
microglia. These data suggest that FXR agonists, such as
GW4064, represent a potential therapeutic approach for
MS which specifically targets peripheral immune cells
including macrophages, but not brain-resident cells,
such as oligodendrocytes, astrocytes or microglia.
Additional file
Additional file 1: Figure S1. Cerebellar oligodendroglial differentiation
is not affected by direct FXR activation or supernatant of FXR-activated
BMMs. Addition of GW4064 during the differentiation of cerebellar
oligodendrocytes over 24 and 48 h does not influence Mbp expression
levels (a) or the percentages of PDGFRα+ OPCs or MBP+ oligodendrocytes
(b, c). Oligodendrocytes of cerebellar origin exhibit no significant difference
in their Mbp expression level when incubated with supernatants from BMM
cultured either in the presence or absence of GW4064 (d). The percentage
of OPCs is unchanged after incubation with BMM-conditioned medium; the
percentage of MBP+ oligodendrocytes is reduced independent of additional
GW4064 treatment (e, f). Activation of FXR cultures using 10 and 20 μM
GW4064 during 14 days of remyelination in cerebellar slice after toxic
demyelination does not alter the ratio of MBP+ and NFL+ axonal fibres (g).
Remyelinated fibres are exemplarily highlighted (arrows). Note that a high
amount of MBP+ debris is still present after 14 days of remyelination (h). In
vitro: n = 3, 1way ANOVA with Bonferroni’s correction, 200 cells per condition
were evaluated, *p < 0.05; ex vivo: n = 2, 1way ANOVA with Bonferroni`s
correction, 6 slices with 3 images each per condition and preparation; all
images are representative. (TIF 5564 kb)
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